

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

				. •		_
In	re	app	าไปใ	۱tk'	on	OΤ
111	10	up	7110	,ui	V11	O1

01

Takeshi NISHIDA et al. : Mail Stop: PCT

Serial No. 10/566,155 : Attorney Docket No. 2006_0088A

Filed January 27, 2006

MEASURING APPARATUS AND METHOD: FOR ULCERATIVE COLITIS DIAGNOSIS AND PROGNOSTIC TEST:

[Corresponding to PCT/JP2004/011278

Filed July 30, 2004]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORITED TO CHARGE ANY DEFICIENCY IN THE FEES FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975

Sir:

la.

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

	each U.S. Patent and U.S. Patent application publication;
0	each reference previously cited in the international application PCT/; and/or
0	each reference previously cited in prior parent application Serial No.
[X] Thi	s Information Disclosure Statement is submitted:
	aree months of the filing date (or of entry into the National Stage) of the attitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. [] that each item of information contained in this Information Disclosure

 Statement was first cited in any communication from a foreign patent office in a

 counterpart foreign application not more than three months prior to the filing of
 the Statement, or
- b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
- 4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. [] a full or partial English language translation submitted herewith,
 - b. [X] an International Search Report (in the English language) submitted herewith,
 - c. [] the concise explanation contained in the specification of the present application at page,
 - d. [X] the concise explanation set forth in the attached English language abstract,
 - e. [X] the concise explanation set forth below or on a separate sheet attached to the reference:

JP 53-22499 is submitted along with a Concise Statement of Relevancy

5. [X] an International Search Report citing one or more of the references is enclosed.

Respectfully submitted,

Takeshi NISHIDA et a

Jeffrey R. Filipek

Registration No. 41,471 Attorney for Applicants

JRF/fs

-Washington, D.C. 20006-1021

Telephone (202) 721-8200

Facsimile (202) 721-8250

March 21, 2006

							19:5				
Sheet 1 of 1 . INFORMATIO				TION DISCLOSURE STATEMENT							
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE				ATTY DOCKET NO. 2006_0088A SERIAL NO. 10/566,155							
PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S)				APPLICANT Takeshi NISHIDA et al.							
(Use several sheets if necessary) Date Submitted to PTO: March 21, 2006				FILING DATE January 27, 2006 GROUP							
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	٨	IAME	CLA	ıss	SUBCLA	ss	FILING DATE APPROPRIA	
	AA	-									-
··	АВ										
	AC								_	. •	
	AD								_		
·	AE										
AF											
	r		FORE	IGN PATENT D	OCUMENTS	r					
		DOCUMENT NUMBER	DATE	со	UNTRY	CLA	ss	SUBCLA	ss	TRANSLATIO YES	NO NO
	AG	7-72154	3-17-95	Ja	apan				\perp	abstract	
	АН	53-22499	3-1-78	Ja	apan					Concise Statement of Relevancy	
	AI	8-304373	11-22-96	Ja	apan					abstract	
	AJ										
	AK									<u>.</u>	
	Y	OTHER	DOCUMENT(S) (I	ncluding Author,	, Title, Date, Pertine	ent Pages,	, Etc.)			<u> </u>	
AL Masaki Nakamura, "Faecal lactate as a disease activity index of ulcerative colitis: Application to assessment of efficacy in treatment with total parenteral nutrition", Journal of the Japanese Society of Gastroenterology, Vol 86, No. 8, pages 1627-1637, August 1989 (along with English abstract on page 1637)											
	АМ	Kiyoko Takamura et al., "Determination of the Free Fatty Acid Content in Fats and Oils by Flow Injection Analysis with Electrochemical Detection", Analytical Sciences, Vol. 11, No. 6, pages 979-982, December 1995									
	AN	P. Vernia et al., "Organic Anions and the Diarrhea of Inflammatory Bowel Disease", Digestive Diseases and Sciences, Vol. 33, No. 11, pages 1353-1358, November 1988									
	AO Gilles Renom et al., "Simple Gas Chromatography Analysis of Faecal Butyrate: Application to Patients at Risk of Pouchitis", Clinical Chemistry and Laboratory Medicine, Vol. 39, No. 1, pages 15-19, 2001									Risk of	
EXAMINER					DATE CONSIDERI	ED					